Common questions about finasteride

In men with complicated LUTS (potentially not just related to BPH) with a combination of storage and voiding symptoms, failure may be due to the chosen medication effectively treating only a portion of their LUTS; as such, additional medication classes should be considered along with procedural options. Therapy should not be continued if patients are neither satisfied nor show a decrease in IPSS. If concordance is lacking, this offers the opportunity to revisit the patient’s priorities and expectations and modify treatment strategies jointly, if indicated.
A 2019 editorial in The BMJ called post-finasteride syndrome “ill defined and controversial”. The status of PFS as a legitimate and distinct medical pathology remains a subject of debate. A separate 2017 retrospective review of nearly 12,000 patients found 1.4% developed persistent (lasting at least 90 days after stopping Finasteride) ED, with this dropping to 0.8% for https://srsbkn.eu.org/ year olds. In October 2024, the EMA had initiated a review of both finasteride and dutasteride due to concerns over potential links to suicidal ideation.
With medical therapy, patients remain in the care of their providers as therapy is ongoing and buy testosterone without prescription renewals are necessary. With this treatment class, perhaps a significant portion of men with BOO who have stopped medical therapy can be treated prior to impending bladder dysfunction. Since many men discontinue medical therapy, yet proportionately few seek surgery, there is a large clinical need for an effective treatment that is less invasive than surgery. Despite the expansion of the treatment algorithm, the ceiling on medical therapy has not been well elucidated. While medications for LUTS attributed to BPH have become the mainstay of therapy, there is wide variability among prescribers with respect to treatment choice (i.e., class of drug, monotherapy versus combination therapy). Multiple studies have found that PVP is safe and effective for patients who continue their anticoagulant/antiplatelet therapy, https://funsilo.date/ with negligible transfusion rates.
A 2010 Cochrane review found that men taking finasteride for BPH (with a mean age of 62.4) are at increased risk for impotence, erectile dysfunction (ED), decreased libido, and ejaculation disorder for the first year of treatment. In 2025, the European Medicines Agency confirmed that suicidal thoughts can occur as a side effect of the hair-loss treatment finasteride and https://sprohr.com/employer/testosterone-levels-by-age-chart-female similar dutasteride. Sexual adverse effects of finasteride and dutasteride have been linked to lower quality of life and ability to maintain an intimate relationship, and can cause stress in relationships.
The first study of finasteride in the treatment of hirsutism in women was published in 1994. By inhibiting these two isozymes of 5α-reductase, finasteride reduces the formation of the potent androgen dihydrotestosterone (DHT) from its precursor buy testosterone without prescription in certain tissues in the body such as the prostate gland, skin, and hair follicles. In 2019, Reuters reported that faulty redactions in court documents revealed allegations from plaintiffs that Merck had known of persistent side effects in their original clinical trials but chose not to disclose them in warning labels. A meta-analysis found a significant association between finasteride use and post-discontinuation depression, suicidal ideation, and sexual dysfunction, dev-gitlab.dev.sww.com.cn but the quality of evidence was limited. It identified three studies that demonstrated full reversibility of side effects and eleven that described patients with irreversible adverse events.